In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 45 for your search:

Drug:  gp100 antigen
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02897, 99-C-0051, CDR0000066963, CCCGHS-NCI-T98-0085, NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682

Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000066097, DUMC-719975, DUMC-0932-99-5R2, DUMC-759-99-5R2, UVA-HIC-7454, NCI-G98-1398, NCT00003229

Phase I/II Study of Ad2/MART-1v2 and Ad2/gp100v2 Melanoma Antigen Vaccines in Patients With Stage II, III, or IV Melanoma (Summary Last Modified 07/2002). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENZ-ADVMEL-001-99, DFCI-00069, GENZ-2000-P-000380/1, NCT00010309

Phase I/II Pilot Study of a Multi-Epitope Peptide Vaccine With Sargramostim (GM-CSF) Plasmid DNA Immune Adjuvant in Patients With Stage IIB, IIC, III, or IV Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Any age (weight > 25 kg)
Sponsor: NCI
Protocol IDs: MSKCC-00142A, 5906, NCI-5906, NCT00085137

Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0023, NCI-T97-0089, T97-0089

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 79
Sponsor: NCI, Other
Protocol IDs: CDR0000066084, UVACC-HIC-7621, UVA-HIC-7621, NCI-G98-1389, NCT00003222

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066176 (10M-97-1), LAC-USC-10M971, LAC-USC-FDR001101, NCI-T97-0100, T97-0100, NCT00003274

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066310 (10M-97-3), LAC-USC-10M973, NCI-G98-1432, NCI-T97-0099, T97-0099, NCT00003339

10.

Phase II Randomized Study of gp100-Tyrosinase Peptide Vaccine Using Sargramostim (GM-CSF), Montanide ISA-51, or QS21 as Adjuvant in Patients with Advanced Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98012, NCI-T97-0110, NCT00003362, T97-0110

11.

Phase II Study of Immunization With gp100 Antigen With Endoplasmic Reticulum Insertion Signal Sequence Alone or in Combination With Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0142, NCI-T98-0036, T98-0036

12.

Phase II Randomized Study of Mutated gp100 Melanoma Peptide With High-Dose Interleukin-2 in HLA-A2.1-Positive Patients With Metastatic Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CWG-UIC-T98-0027, NCI-T98-0027, NCT00003568, T98-0027

13.

Phase II Randomized Study of Mutated gp100 Melanoma Vaccine in HLA-A2-Positive Patients With at Least 1 mm Melanoma on Initial Biopsy. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: NCI
Protocol IDs: PPMC-IRB-99-9, NCI-T98-0081, NCT00003895, T98-0081

14.

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832

15.

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000067391, NCI-99-C-0159, NCI-T99-0079, T99-0079, NCT00019994

16.

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02337, CLB-509901, U10CA031946, CDR0000067886, CALGB-509901, NCT00005949

17.

Phase II Randomized Study of Immunization With an HLA-A2 Multiepitope Peptide Vaccine Comprising MART-1:27-35, gp100:209-217 (210M), and Tyrosinase:368-376 (370D) Peptides Alone or in Combination With Sargramostim (GM-CSF) and/or Interferon alfa-2b in HLA-A2 Positive Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1696, NCT00006385, E1696

18.

Vaccine Therapy in Treating Patients With Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000068299, NCI-00-C-0216, NCI-2391, 2391, NCT00020358

19.

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069220 (10M-01-1), LAC-USC-10M011, LAC-USC-IRB-013030, NCI-5506, 5506, NCT00031733

20.

Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) Combined With gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-02-C-0106H, NCI-5743, 5743, NCT00032045

21.

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 030172, 03-C-0172, NCI-03-C-0172, NCI-6211, 6211, NCT00062218, NCT00059475

22.

Phase II Randomized Study of Immunization With MAGE-3, Melan-A, gp100 Antigen, and NA17-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells and Interleukin-12 With or Without Low-Dose Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-11447A, NCI-1330, NCT00064168, 1330

23.

Phase II Randomized Study of Immunization With Recombinant gp100 Protein (184V) Emulsified in Montanide ISA-51 With or Without gp100:209-217 (210M) Peptide in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-03-C-0299, NCI-6210, 6210, NCT00072085

24.

Phase II Randomized Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) With or Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0083, MDX-010-19, NCI-6532, 6532, NCT00077532

25.

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000365467, P30CA076292, P30CA014089, MCC-15241, MDX010-16, NCI-6446, CA184-016, 6446, LAC-USC-10M036, NCT00084656

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map